抗瘤增效方联合吉非替尼治疗老年非小细胞肺癌患者及对炎症因子,T细胞亚群水平及血清肿瘤标志物的影响  

Effect of Kangliu Zengxiao Formula Combined with Gefitinib in Treating Elderly Non-small Cell Lung Cancer and on Inflammation Factors,Level of T Cell Subsets and Serum Tumor Markers

作　　者：马东阳 耿良 胡彦辉 崔庆丽 刘怀民 

机构地区：[1]郑州大学附属肿瘤医院,郑州450008

出　　处：《中国实验方剂学杂志》2017年第7期173-178,共6页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：河南省医学科技攻关计划项目(201304056)

摘　　要：目的:探讨抗瘤增效方联合吉非替尼治疗老年非小细胞肺癌及对患者炎症因子,T细胞亚群水平及血清肿瘤标志物影响。方法:选取郑州大学附属肿瘤医院肿瘤内科非小细胞肺癌Ⅳ期老年患者84例,患者或家属签字同意,积极配合此次研究,按随机数字表法分组,对照组患者(42例)予以单纯吉非替尼治疗,研究组患者(42例)予以吉非替尼联合抗瘤增效方治疗,观察并记录所有患者治疗前后生存质量、炎症因子及T细胞亚群水平,同时对比临床疗效及不良反应状况。结果:对照组有效率低于研究组(P<0.05);与治疗前比较,两组患者治疗后生存质量、炎症因子及T细胞亚群水平均发生变化,研究组治疗后躯体功能,角色功能,社会功能,情绪功能评分高于对照组,研究组治疗后白细胞介素-2(interleukin-2,IL-2),白细胞介素-12(interleukin-12,IL-12)和γ-干扰素(interferon-γ,IFN-γ)水平高于对照组,研究组治疗后CD8+水平低于对照组,CD4+及CD4+/CD8+水平高于对照组(P<0.05);治疗后,对照组血管内皮生长因子(vascular endothelial growth factor,VEGF)升高,治疗组VEGF下降(P<0.05);与治疗前比较,两组患者癌胚抗原(carcinoembryonic antigen,CEA),糖抗原(carbohydrate antigen-125,CA125)及细胞角蛋白19片段21-1(cytokeratin 19 fragments,CYFRA21-1)差异无统计学意义,组间比较差异无统计学意义;两组患者不良反应较轻,无药物不良反应。结论:抗瘤增效方联合吉非替尼治疗老年非小细胞肺癌疗效确切,能提高生活质量及免疫功能。Objective： To investigate the effect of Kangliu Zengxiao formula combined with gefitinib in treating elderly non-small cell lung cancer and on inflammation factors, level of T cell subsets and serum tumor markers. Method： The 84 cases of elderly non-small cell lung cancer were selected, and the patients or their family members signed the informed consent toactively cooperate with the study. They were divided into 2 groups. The 42 patients in control group were treated with gefitinib alone, while the 42 patients in treatment group received Kangliu Zengxiao formula. Quality of life, inflammatory cytokines and T lymphocyte subsets, and the clinical efficacy and adverse reactions were observed and compared. Result： The control group was inferior to treatment group in effective rate （P 〈 0.05）. Compared with before treatment, survival quality, inflammatory cytokines and T cell subsets level changed in both groups. Compared with the control group, body function, role function, social function, emotional function score, levels of interleukin-2 （ IL-2 ）, interleukin-12 （ IL-12 ） and interferon-T （ IFN-T） were higher in treatment group, with lower CD8 ^＋ level, and CD4 ^＋ and CD4 ^＋/CD8 ^＋ levels were higher in control group （P 〈 0.05）. After treatment, vascular endothelial growth factor （VEGF） increase dinthe control group, whereas treatment group showed decreased VEGF （P 〈 0.05）. Compared with before treatment, the two groups showed no statistically significant difference in carcino embryonic antigen （CEA）, carbohydrate antigen-125 （CA125） and cytokeratin 19 fragments （CYFRA21-1）, with no inter-group statistical significance. Adverse reactions in two groups were mild, with no adverse drug reaction. Conclusion： Kangliu Zengxiao formula combined with gefitinib in the treatment of elderly non-small cell lung cancer was effective, and can improve the life quality and immune function.

关 键 词：抗瘤增效方 吉非替尼 非小细胞肺癌 炎症因子 T细胞亚群 肿瘤标志物 

分 类 号：R287[医药卫生—中药学] R734.2[医药卫生—中医学]